Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Reveals Positive Phase III Data For Platelet Drug Romiplostim

This article was originally published in The Pink Sheet Daily

Executive Summary

Strong efficacy findings should aid company’s race with GSK to get chronic ITP treatment to market.

You may also be interested in...



Amgen’s Platelet Booster Faces FDA Panel

Risk management plan is likely focus of March 12 ODAC meeting.

Amgen’s Platelet Booster Faces FDA Panel

Risk management plan is likely focus of March 12 ODAC meeting.

Amgen’s March Madness: ESAs, Nplate To Get FDA Advisory Panel Review

Schering’s PegIntron in melanoma will also be reviewed at March 12-13 meeting of FDA’s Oncologic Drugs Advisory Committee.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel